Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
A close FDA committee vote to authorize molnupiravir indicates that mAbs could still be favored for Covid-19 when available.
By
William Newton
William Newton is a reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on rare diseases, Covid-19 antivirals, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
By
Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial
As breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.
By
Retrotope eyes $100m raise for neurodegenerative disease platform
California-based Retrotope aims to expand its investor pool as it prepares to potentially go public in the coming years.
By
Ampio open to CRO offers to run Phase I long hauler Covid study scheduled to start 1Q, CEO says
Ampio Pharmaceuticals welcomes CRO pitches for a Phase I trial of nebulised Ampion for "long hauler" Covid patients with…
By
Quercis enlists Clinipace for Phase III trial in pancreatic cancer-related venous thromboembolism; in $40m-$60m fundraise, CEO says
Quercis Pharma is working with the CRO Clinipace in a Phase III trial of Kinisoquin (isoquercetin) for venous thromboembolism…
By
Covaxx commissions CRO PPD for Phase II/III Covid-19 vaccine trial in Brazil, CEO says
Covaxx has hired CRO PPD for a Phase II/III trial of its Covid-19 vaccine candidate UB-612 in Brazil beginning…
By
BirchBioMed to seek a CRO in about two months for topical scarring study, CEO says
BirchBioMed will begin reviewing CRO pitches for a Phase III trial of FS2 for topical scarring in approximately two…
By
Adastra eyes CRO pitches for Phase II trial of anticancer candidate; initiates $45m Series B fundraising, exec says
In addition, the company has initiated a $45m Series B round to finance the study and other clinical trial…
By